Agilis Biotherapeutics Co-Sponsors FAST-FIRE Research Event

Fund-Raiser Supports Research for Angelman Syndrome

Cambridge, MA, September 14, 2015 -- Agilis Biotherapeutics, LLC (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that Agilis was a co-sponsor of the Foundation for Angelman Syndrome Therapeutics' (FAST) "Lite the Night on FIRE" research fund-raising event in Boston, MA. Mark Pykett, President and CEO of Agilis, gave a brief talk discussing the use of gene therapy in the potential treatment of Angelman Syndrome. Dr. Pykett highlighted Agilis' collaboration on Angelman Syndrome gene therapy with Edwin Weeber, Ph.D., Professor, Molecular Pharmacology and Physiology, Chief Scientific Officer, USF Health Byrd Alzheimer's Institute and Director, Neurobiology of Learning and Memory Laboratory at the University of South Florida. Dr. Weeber has been the recipient of grant awards from FAST in their FAST-TRAC (Targeted Research to Advance a Cure) and FAST-FIRE (Integrative Research Environment) programs. Dr. Weeber has published recent scientific findings on potential treatment approaches for Angelman Syndrome with gene therapy using the UBE3A gene and supplementation of the Reelin protein. Dr. Pykett also discussed Agilis' sponsored research and license agreements with the University of South Florida for Angelman Syndrome.

"Agilis is honored to co-sponsor and participate in the FAST FIRE event," stated Dr. Pykett. "The Foundation for Angelman Syndrome Therapeutics is an inspiring organization committed to helping the Angelman community in myriad ways. We are thrilled to be able to work with them and to continue to focus on expediting our gene therapy program for Angelman Syndrome to a pioneering first-in-man study."

FAST is an organization of families and professionals dedicated to finding a cure for Angelman Syndrome and related disorders through the funding of an aggressive research agenda, education, and advocacy. FAST's grants and fellowship programs encourage research aimed at finding a treatment for Angelman Syndrome.

About Agilis Biotherapeutics, LLC

Agilis is advancing innovative DNA therapeutics designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system. Our therapies are engineered to impart sustainable clinical benefits, and potentially a functional cure, by inducing persistent expression of a therapeutic gene. The Company's technology is aimed at the precise targeting and restoration of lost gene function, while avoiding unintended off-target effects. Our integrated strategy increases the efficiency of developing DNA therapeutics into safe, targeted gene therapies that achieve long-term efficacy and enable patients to remain asymptomatic without continuous invasive treatment. Agilis' rare disease programs are focused on gene therapy for Friedreich's Ataxia, Angelman Syndrome and Fragile X Syndrome, rare genetic diseases that include severe neurological deficits and result in physically debilitating conditions. Friedreich's Ataxia is the most common hereditary ataxia with an estimated 5,000 to 10,000 patients in the U.S. There are an estimated 10,000 to 15,000 people living with Angelman Syndrome in the US. Fragile X Syndrome is the most common known cause of inherited intellectual disability with an estimated 64,000 patients living in the U.S.

We invite you to visit our website at www.agilisbio.com

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

###

For more information contact:

Agilis Biotherapeutics

Dr. Jodi Cook

Vice President, Operations

Email: jcook@agilisbio.com

Phone: 510-673-7809